Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2010
09/30/2010US20100249029 Peptides with high affinity for the prolactin receptor
09/30/2010US20100249028 Oral composition
09/30/2010US20100249027 Crf conjugates with extended half-lives
09/30/2010US20100249026 Albumin fusion proteins
09/30/2010US20100249025 Peptide antagonists of vascular endothelial growth factor
09/30/2010US20100249024 Cetp inhibitors
09/30/2010US20100249023 Isoflavone formulation
09/30/2010US20100249022 Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
09/30/2010US20100249021 Method and medicament for inhibiting the infection of influenza virus
09/30/2010US20100249020 Fast-acting insulin formulation
09/30/2010US20100249019 Use of a peptide as a therapeutic agent
09/30/2010US20100249018 Composition and method for preventing and treating immune-related disorder
09/30/2010US20100249017 Use of cnp-22, alone or in combination with physalemin, as a therapeutic agent
09/30/2010US20100249016 Metal-binding compounds and uses therefor
09/30/2010US20100249015 Use of VEGF in the Treatment of Retarded Fetal Growth in Pregnancy
09/30/2010US20100248336 Methods for purifying nucleic acids
09/30/2010US20100248334 Biological active coating components, coatings, and coated surfaces
09/30/2010US20100248241 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
09/30/2010US20100247734 Methods for Making Nutritional Compositions Comprising Curcuminoids
09/30/2010US20100247693 Cosmetic formulation to treat rosacea telangiectasia
09/30/2010US20100247688 Pirenzepine and derivatives thereof as anti-amyloid agents
09/30/2010US20100247662 Biologic Modulations with Nanoparticles
09/30/2010US20100247661 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces
09/30/2010US20100247657 Telomerase reverse transcriptase variant
09/30/2010US20100247655 Synthesis of Small Particles
09/30/2010US20100247652 Alginate Biomaterials for the Treatment of Hepatic Disorders
09/30/2010US20100247651 Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
09/30/2010US20100247650 Treatment for pre-eclampsia in pregnant women using targeted apheresis
09/30/2010US20100247648 Antimicrobial compounds
09/30/2010US20100247638 organoleptically improved dietary fiber composition and a process thereof (teestar)
09/30/2010US20100247633 Polypeptide Films and Methods
09/30/2010US20100247627 Foxn1 and pigmentation
09/30/2010US20100247625 Orally Bioavailable Lipid-Based Constructs
09/30/2010US20100247618 Novel synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
09/30/2010US20100247608 Pharmaceutical compositions comprising hgh for oral delivery
09/30/2010US20100247595 Porous structures and methods of use
09/30/2010US20100247594 Delivery of dry formulations of octreotide
09/30/2010US20100247562 Complexes Derived from Heterohybrid Cells and Uses Thereof
09/30/2010US20100247558 PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE
09/30/2010US20100247553 Goodpasture Antigen Binding Protein
09/30/2010US20100247552 Pak modulators
09/30/2010US20100247548 Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
09/30/2010US20100247544 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms
09/30/2010US20100247543 Treatment and prevention of neurodegenerative diseases
09/30/2010US20100247538 IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
09/30/2010US20100247534 Fused heterocyclic compounds as inhibitors of potassium channel function
09/30/2010US20100247528 Arrays, kits and cancer characterization methods
09/30/2010US20100247525 Compositions and methods for treating anthrax lethality
09/30/2010US20100247520 Mutated netrin 4, fragments thereof and uses thereof as drugs
09/30/2010US20100247518 Modified proteins, designer toxins, and methods of making thereof
09/30/2010US20100247516 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
09/30/2010US20100247513 Treatment of carpal tunnel syndrome by injection of the flexor retinaculum
09/30/2010US20100247512 Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
09/30/2010US20100247511 Methods and compositions for activated protein c with reduced anticoagulant properties
09/30/2010US20100247510 agent for reducing a side effect of an anticancer drug
09/30/2010US20100247509 Fusion Proteins
09/30/2010US20100247508 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
09/30/2010US20100247507 Instant enzyme formulations for animal nutrition
09/30/2010US20100247506 Formation of stable submicron peptide or protein particles by thin film freezing
09/30/2010US20100247496 Neuronal viability factor and use thereof
09/30/2010US20100247490 SIMIAN E ADENOVIRUSES SAdV-39, -25.2, -26, -30, -37, AND -38
09/30/2010US20100247484 Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
09/30/2010US20100247483 Therapeutic agent composition and method of use
09/30/2010US20100247482 Tight junction modulator peptides for enhanced mucosal delivery of therapeutic compounds
09/30/2010US20100247481 Abcb1 genotyping to predict microtubule-stabilizing-agent-induced toxicity
09/30/2010US20100247463 N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
09/30/2010US20100247460 Silicone Organic Elastomer Gels From Organopolysiloxane Resins
09/30/2010US20100247454 Compositions for elastogenesis and connective tissue treatment
09/30/2010US20100247452 Use of erythropoietin
09/30/2010US20100247451 Use of erythropoietin
09/30/2010US20100247450 Use of erythropoietin
09/30/2010US20100247437 Materials and methods for the delivery of biomolecules to cells of an organ
09/30/2010US20100247434 Anti-Angiogenic Extracts from Pomegranate
09/30/2010US20100247433 Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
09/30/2010CA2756997A1 Fertilization modulation compounds and process for implementing them
09/30/2010CA2756801A1 Tissue kallikrein for the treatment of pancreatic .beta.-cell dysfunction
09/30/2010CA2756785A1 Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy
09/30/2010CA2756574A1 Methods for improving neurological outcome after neural injury and neurodegenerative disease
09/30/2010CA2756572A1 Promotion of neuronal integration in neural stem cell grafts
09/30/2010CA2756412A1 Compositions for stimulation of mammalian innate immune resistance to pathogens
09/30/2010CA2756170A1 Glycoconjugate vaccines
09/30/2010CA2756168A1 Isoform nell-1 peptide
09/30/2010CA2756107A1 Composition for regulating autonomic nervous activity and method for regulating autonomic nerve
09/30/2010CA2755983A1 Compounds and methods for modulating an immune response
09/29/2010EP2233926A2 Breast Endothelial Cell Expression Patterns
09/29/2010EP2233576A1 Modified coagulation factor VIIa with extended half-life
09/29/2010EP2233574A1 Mammalian cytokine: interleukin-B30 and related reagents
09/29/2010EP2233572A2 Genes and polypeptides relating to human colon cancers
09/29/2010EP2233571A1 Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
09/29/2010EP2233498A1 Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same
09/29/2010EP2233495A1 Glycosylated glycopeptide antibiotic derivative
09/29/2010EP2233156A2 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
09/29/2010EP2233150A2 Erythropoietin for use in the treatment of wounds or the transplantation of cells
09/29/2010EP2233149A1 Combination of BLYS inhibition and anti-CD20 agents for treatment of autoimmune disease
09/29/2010EP2233148A1 Uses of pdcd5 polypeptide for tumor chemotherapy and organ protection
09/29/2010EP2233137A2 Calcium receptor activator
09/29/2010EP2231702A1 Protease inhibitor
09/29/2010EP2231701A2 Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
09/29/2010EP2231695A1 Antitumoral compounds
09/29/2010EP2231694A1 Cationic core-shell peptide nanoparticles
1 ... 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 ... 3163